Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q1 2025 · 10-Q
Revenue$70.00K$70.00K−79.0% vs Q1 2024 Net Income-$1.50M-$1.50MN/M vs Q1 2024 EPS Diluted-$2.52-$2.52N/M vs Q1 2024 Gross Profit$50,000−70.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Operating Cash Flow-$889,000N/M Free Cash Flowderived-$889,000— Margins · derivedGross margin71.4%+21.4 pt vs Q1 2024
Operating margin-1967.1%−1523.7 pt vs Q1 2024
Net margin-2145.7%−1702.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end